# Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

> **NCT02525653** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Lung Cancer
- Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

## Interventions

- **DRUG:** albumin-bound paclitaxel
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT02525653
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2019-05
- **Final completion:** 2019-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-01-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02525653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02525653, "Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02525653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*